The ethical concerns surrounding the non-disclosure of genetic risks to participants in Alzheimer’s anti-amyloid drug trials have sparked significant debate. Eisai and Eli Lilly, the companies conducting these trials, were aware of the increased risk of brain swelling and bleeding in participants
Randomized controlled trials (RCTs) are the cornerstone of evidence-based medicine, providing the highest level of evidence for the efficacy and safety of new drugs and medical devices. However, traditional RCTs often face significant challenges, including high costs, complex governance, and
In an optimistic outlook at the 43rd JPM Conference in San Francisco, Thermo Fisher CEO Marc Casper underscored the firm's strategic adaptations and growth initiatives tailored to meet surging demand for GLP-1 diabetes and weight loss products. Thermo Fisher Scientific's extensive investment in its
Researchers from the Stevens Institute of Technology have developed an advanced software tool named "clipping spline," which offers unprecedented capabilities for viewing and analyzing complex 3D biomedical images. This innovation enables deep and comprehensive visualization of optical coherence
In a breakthrough development for cancer treatment and deep tissue imaging, researchers at Tokyo Metropolitan University have created a revolutionary dye. This innovative dye is derived from the bile pigment bilatriene and incorporates a unique ring structure designed to bind rhodium and indium
The quest for improved treatment options for metastatic colorectal cancer (mCRC) patients with the BRAF V600E mutation has always been fraught with challenges. Given the aggressive nature of these tumors and the historically poor prognosis associated with this genetic mutation, researchers have
